Phillips Wealth Planners LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,550 shares of the company's stock, valued at approximately $492,000.
Other institutional investors also recently bought and sold shares of the company. Perigon Wealth Management LLC boosted its stake in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock worth $367,000 after acquiring an additional 201 shares during the last quarter. HBK Sorce Advisory LLC boosted its stake in shares of Sanofi by 12.5% in the first quarter. HBK Sorce Advisory LLC now owns 4,799 shares of the company's stock worth $266,000 after acquiring an additional 532 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Sanofi by 570.6% in the first quarter. Bessemer Group Inc. now owns 4,339 shares of the company's stock worth $240,000 after acquiring an additional 3,692 shares during the last quarter. Finally, Golden State Equity Partners acquired a new stake in shares of Sanofi in the first quarter worth approximately $246,000. 14.04% of the stock is owned by institutional investors and hedge funds.
Sanofi Stock Performance
NASDAQ SNY opened at $47.80 on Thursday. The stock's fifty day moving average is $51.06 and its two-hundred day moving average is $52.00. The firm has a market capitalization of $117.23 billion, a P/E ratio of 17.07, a price-to-earnings-growth ratio of 1.00 and a beta of 0.50. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the previous year, the business earned $1.78 earnings per share. The company's revenue for the quarter was down 11.0% on a year-over-year basis. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a $2.0369 dividend. The ex-dividend date was Friday, May 9th. This represents a yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 57.14%.
Wall Street Analysts Forecast Growth
SNY has been the topic of a number of research analyst reports. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $61.50.
Check Out Our Latest Report on Sanofi
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
